The Isotype of Autoantibodies Influences the Phagocytosis of Antibody-Coated Platelets in Autoimmune Thrombocytopenic Purpura

Scandinavian Journal of Immunology

Volumn 74, Issue 5, 2011, Pages 489-495

  Hoemberg, M ^a,b   Stahl, D ^c,d   Schlenke, P ^a   Sibrowski, W ^a   Pachmann, U ^e   Cassens, U ^f  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d Haema AG   (Germany)

^e Center of Transfusion Medicine   (Germany)

^f KLINIKUM DORTMUND   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIBODY ISOTYPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; MONOCYTE; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; SENSITIZATION; THROMBOCYTE; THROMBOCYTE ADHESION;

ADULT; ANTIGENS, CD14; AUTOANTIBODIES; BLOOD PLATELETS; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTEGRIN BETA3; MONOCYTES; PHAGOCYTOSIS; PLATELET ADHESIVENESS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; THROMBOCYTOPENIA;

EID: 80053481554     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02600.x     Document Type: Article

References (47)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
2. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364-9.
3. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009;146:585-96.
4. Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007;44:S12-23.
5. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13.
6. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
7. Semple JW, Milev Y, Cosgrave D et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-54.
8. Semple JW. Pathogenic T-cell responses in patients with autoimmune thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25 (Suppl. 1):S11-3.
9. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003;17:69-80.
10. Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104:442-7.
11. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194-201.
12. Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood 1997;89:1112-4.
13. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am 2007;21:743-59, vii.
14. Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: a target for immunomodulation? J Clin Invest 2008;118:2677-81.
15. Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25 (Suppl. 1):S14-8.
16. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986;314:1236-9.
17. Carcao MD, Blanchette VS, Wakefield CD et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003;120:135-41.
18. van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998;48:222-32.
19. Crow AR, Song S, Siragam V, Lazarus AH. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 2006;47:710-3.
20. AABB. American Association of Blood Banks: Technical Manual, 15th edn. AABB: Bethesda, 2005; ISBN 1-56395-196-7.
21. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody - specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722-6.
22. Lim J, Kim Y, Han K et al. Flow cytometric monocyte phagocytic assay for predicting platelet transfusion outcome. Transfusion 2002;42:309-16.
23. Baker GR, Sullam PM, Levin J. A simple, fluorescent method to internally label platelets suitable for physiological measurements. Am J Hematol 1997;56:17-25.
24. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991;31:409-14.
25. Rinder HM, Snyder EL, Bonan JL, Napychank PA, Malkus H, Smith BR. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and beta-thromboglobulin release. Transfusion 1993;33:25-9.
26. Handin RI, Stossel TP. Phagocytosis of antibody-coated platelets by human granulocytes. N Engl J Med 1974;290:989-93.
27. Tsubakio T, Kurata Y, Kanayama Y, Yonezawa T, Tarui S, Kitani T. In vitro platelet phagocytosis in idiopathic thrombocytopenic purpura. Acta Haematol 1983;70:250-6.
28. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol 2004;5:685-92.
29. Garza KM, Chan SM, Suri R et al. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 2000;191:2021-7.
30. Semple JW. T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura. Transfus Apher Sci 2003;28:237-42.
31. Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol 2005;81:106-12.
32. Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci. 1998;19:245-51.
33. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-50.
34. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2003;122:818-24.
35. Freedman J, Garvey MB, Elinder G, Blanchette VS. Directions for research in autoimmune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998;424:82-4.
36. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994;83:1024-32.
37. Porcelijn L, von dem Borne AE. Immune-mediated thrombocytopenias: basic and immunological aspects. Baillieres Clin Haematol 1998;11:331-41.
38. Stahl D, Hoemberg M, Cassens U, Pachmann U, Sibrowski W. Evidence that human autoimmune thrombocytopenia mediated by both immunoglobulin isotypes IgM and IgG is an independent disease entity. Eur J Haematol 2005;75:318-27.
39. Cines DB, McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 2007;14:511-4.
40. Olsson B, Andersson PO, Jernas M et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-4.
41. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007;44:S3-11.
42. Hauch TW, Rosse WF. Platelet-bound complement (C3) in immune thrombocytopenia. Blood 1977;50:1129-36.
43. Kurata Y, Curd JG, Tamerius JD, McMillan R. Platelet-associated complement in chronic ITP. Br J Haematol 1985;60:723-33.
44. Maliszewski CR, March CJ, Schoenborn MA, Gimpel S, Shen L. Expression cloning of a human Fc receptor for IgA. J Exp Med 1990;172:1665-72.
45. McDonald KJ, Cameron AJ, Allen JM, Jardine AG. Expression of Fc alpha/mu receptor by human mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy. Biochem Biophys Res Commun 2002;290:438-42.
46. Shibuya A, Sakamoto N, Shimizu Y et al. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol 2000;1:441-6.
47. Shibuya A, Honda S. Molecular and functional characteristics of the Fcalpha/muR, a novel Fc receptor for IgM and IgA. Springer Semin Immunopathol 2006;28:377-82.